GH-axis research
Ipamorelin
Peptide di ricerca liofilizzato sulla segnalazione endocrina per la revisione dei sistemi
Ipamorelin is a selective growth hormone secretagogue receptor research peptide used in GH-release and endocrine-signaling comparisons.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca Ipamorelin
Ipamorelin is a pentapeptide growth hormone secretagogue studied for activity at the ghrelin receptor, also known as GHS-R1a. Experimental work compares GH-release response, pharmacokinetics, receptor selectivity, and effects on other endocrine markers with older secretagogues such as GHRP-2, GHRP-6, and hexarelin. It differs from CJC-1295 and sermorelin because those compounds act through the GHRH receptor rather than GHS-R. Ipamorelin is therefore a focused choice for secretagogue and receptor-selectivity studies, either alone or as a comparator in GH-axis designs. Early human PK/PD literature exists, but it does not validate a research-use catalog lot.
Molecular class
Five-residue ghrelin-receptor secretagogue
Sequence / composition
Aib-His-D-2-Nal-D-Phe-Lys-NH2; a short sequence containing non-proteinogenic and D-amino-acid residues.
Research design note
The stereochemical substitutions are part of the construct and should be preserved in identity testing.
Meccanismo proposto
A pentapeptide agonist at the growth-hormone secretagogue receptor GHS-R1a. Receptor activation engages Gq-related signaling in pituitary and hypothalamic systems and stimulates growth-hormone release.
Effetti riportati negli studi
- Animal and human pharmacology studies reported dose-dependent GH release after ipamorelin exposure.
- Comparative studies described greater GH selectivity and less ACTH or cortisol stimulation than some older GHRP compounds under studied conditions.
- It remains a ghrelin-receptor agonist, and selectivity does not mean absence of all off-target or systemic effects.
Endpoint di ricerca comuni
GHS-R1a potency, calcium or second-messenger response, GH concentration and pulse shape, ACTH, cortisol, prolactin, appetite markers, pharmacokinetics, and desensitization.
Evidenze e limiti
Preclinical and early controlled human PK/PD evidence exists. Long-term human outcomes and equivalence of catalog material are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Open the direct COA link on this page. For other batch documents, contact support with the product name and any relevant order or batch reference.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.